Conclusion
The combination of iPSC and CAR technologies provides an extraordinary opportunity to oncology and greatly facilitates cell-based therapy for cancer patients. This system offers researchers and clinicians efficient and safe ways of generating iPSC-derived T cells as an unlimited T-cell source for therapeutic purposes. Although the pre-clinical and clinical studies concerning the combination of iPSC and CAR technologies are not sufficient, these pioneer studies that we describe here shed light on the applicability and feasibility of off-the-shelf T cells and CAR iPSC-derived T cells development. Off-the-shelf CAR iPSC-derived T cells offer that a novel universal CAR-T cell is on its way to clinical use.